Safe, effective procedures
Jeremy N. Ruskin, MD
Founder and Director Emeritus;
Cardiac Arrhythmia Service, Massachusetts General Hospital;
Professor of Medicine, Harvard Medical School
“Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance.”
AblaCor™ Medical Corporation’s mission is to develop innovative products to significantly advance Atrial Fibrillation (AFib) treatment. The Company’s goal is to provide patients with long-term freedom from AFib without multiple ablation procedures.
AblaCor’s first product, the CircumBlator™ AF Catheter Ablation System, is uniquely designed to deliver pulmonary vein isolation (PVI) in a “single-shot" circumferential ablation compared to currently marketed “point-by-point” and “balloon” technologies.
AblaCor's Scientific Advisors
The CircumBlator™ AF Catheter Ablation System is not approved for human use.
Continuous tissue contact for precise lesion formation the first time
Improved patient outcomes
Fewer repeat procedures
Reduced healthcare costs
Lawrence S. Rosenthal MD, PhD, FACC, FHRS
Director, Electrophysiology Service;
Professor of Medicine, UMass Memorial Medical Center
Controlled energy delivery